$APS.TO

2 stories mentioning APS.TO

Every FINWIRES story that references APS.TO, newest first.

Aptose Biosciences Updated Tuscany Trial Data Reported in Oral Presentation at EHA 2026

Aptose Biosciences (APS.TO) Monday said updated data from its Phase 1/2 Tuscany trail showed that the addition of tuspetinib to standard therapy was well-tolerated in newly diagnosed patients with AML.The data was highlighted in an oral presentation on Sunday at the European Hematology Association Congress (EHA 2026) in Stockholm, Sweden.According to a statement, tuspetinib in combination with standard of care dosing with venetoclax and azacitidine, creates a "well-tolerated and mutation agnostic" frontline triple drug therapy for newly diagnosed AML patients.Thirty-two patients were dosed at varying levels. Composite complete response (CRc) rate in evaluable patients across all dosing groups was 86.2%, the company said.MRD-negativity, which measures the presence of cancer cells after treatment, was 86.4% in patients who achieved complete response or CRh.Aptose shares closed unchanged at $2.19 on Friday on the Toronto Stock Exchange.

$APS.TO

Mining & Metals17d ago

Aptose Biosciences Says Acquisition by Hanmi Delayed Until June

Aptose Biosciences' (APS.TO) acquisition by Hanmi has been further delayed as certain Korean regulatory approvals remain in progress, the company said on Friday.The parties do not anticipate that the review will prevent closing and are working toward completing the arrangement in June, a statement said.The company has received an additional advance of US$2.0 million from Hanmi as part of a US$11.9 million loan amended facility agreement announced last year. To date, Aptose has received US$9.9 million. The funds enable uninterrupted continuance of the Tuscany clinical trial with tuspetinib in combination with venetoclax and azacitidine for the frontline treatment of newly diagnosed acute myeloid leukemia (AML).Aptose shares closed unchanged at $2.28 on Thursday on the Toronto Stock Exchange.

$APS.TO